The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China

Background: The clinical significance of protein tyrosine phosphatase nonreceptor type 11 mutation (PTPN11^mut ) in acute myeloid leukemia (AML) is underestimated.

Methods: We collected the data of AML patients with mutated PTPN11 and wild-type PTPN11 (PTPN11^wt ) treated at our hospital and analyzed their clinical characteristics and prognosis.

Results: Fifty-nine PTPN11^mut and 124 PTPN11^wt AML patients were included. PTPN11^mut was more common in myelomonocytic and monocytic leukemia, and was more likely to co-mutate with KRAS, KMT2C, NRAS, U2AF1, NOTCH1, IKZF1, and USH2A mutations than PTPN11^wt . The overall survival for AML patients with PTPN11^mut was significantly shorter than that for those with PTPN11^wt (p = 0.03). The negative impact of PTPN11^mut on overall survival was pronounced in the "favorable" and "intermediate" groups of ELN2017 risk stratification, as well as in the wild-type NPM1 group (p = 0.01, p = 0.01, and p = 0.04).

Conclusion: PTPN11^mut is associated with distinct clinical and molecular characteristics, and adverse prognosis in AML patients.